Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
OneSource Specialty Pharma Pretax Margin % Related Terms
OneSource Specialty Pharma Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544292 vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma (BOM:544292) has a Pretax Margin % of 4.52% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on OneSource Specialty Pharma and its competitors. According to the industry distribution chart, OneSource Specialty Pharma ranks #303 out of 942 companies in the Biotechnology industry, placing it in the top 32.2%.
Is OneSource Specialty Pharma's Pretax Margin % too high?
OneSource Specialty Pharma's current Pretax Margin % is 4.52%. Based on the distribution chart, OneSource Specialty Pharma ranks #303 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #303 out of 942 companies for Pretax Margin %. This puts OneSource Specialty Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on OneSource Specialty Pharma and its competitors. OneSource Specialty Pharma's current Pretax Margin % is 4.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (BOM:544292) has a current Pretax Margin % of 4.52%. The current Pretax Margin % is 4.52%. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For OneSource Specialty Pharma (BOM:544292), the current Pretax Margin % is 4.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for BOM:544292
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544292 has been successfully added to your 
